Skip to main content

Table 2 Demographics, serum biomarkers, pulmonary function tests, six-minute walk test, arterial blood gas analysis, and treatment at the time of registration for lung transplantation (n = 118)

From: Clinical significance of radiological pleuroparenchymal fibroelastosis pattern in interstitial lung disease patients registered for lung transplantation: a retrospective cohort study

 

With rPPFE

Without rPPFE

P

Number

30

88

Demographics

 Age

45.5 (37, 51)

51 (43, 56)

0.05

 Male

13 (43.3)

58 (65.9)

0.03

 Ever-smoking

8 (26.7)

54 (61.4)

0.001

 Previous pneumothorax

24 (80.0)

23 (26.1)

< 0.001

 Family history

2 (6.7)

21 (23.9)

0.16

 mMRC [1]

3 (3, 4)

4 (3, 4)

0.15

 BMI

15.9 (14.8, 17.2)

21.5 (18.8, 25.1)

< 0.001

Serum biomarkers

 KL-6, IU/L

542 (402, 698)

1460 (933, 2150)

< 0.001

 LDH, IU/L

186.5 (172, 212)

229 (202, 271)

< 0.001

Pulmonary function tests

 %FVC

35.75 (22.6, 46.2)

48.5 (37.6, 62.0)

< 0.001

 %DLCO

45.5 (37, 51)

24.4 (17.4, 31.9)

0.002

Six-minute walk test

 Distance, meter

375 (243, 500)

333 (235, 454)

0.36

 Distance < 250 m

8 (26.7)

26 (29.5)

0.82

 Lowest SpO2, %

87.5 (81, 93)

81 (76, 87)

< 0.001

Arterial blood gas analysis

 PaO2, Torr

77.8 (65.4, 86.6)

74.05 (63.4, 87.9)

0.73

 PaCO2, Torr

49.55 (45.6, 56.9)

43.55 (40.7, 47.55)

< 0.001

Treatment

 Corticosteroid

11 (36.7)

62 (70.5)

0.002

 IS agent

3(10.0)

40 (45.5)

< 0.001

 Antifibrotic agent

7 (23.3)

39 (44.3)

0.05

 LTOT

15 (50.0)

63 (71.6)

0.04

  1. Data are presented as number (percentage) or median (interquartile range)
  2. Abbreviations: PPFE plueroparenchymal fibroelastosis, rPPFE radiological PPFE, mMRC modified Medical Research Council dyspnea scale, BMI body mass index, KL-6 Krebs von der Lungen-6, LDH lactate dehydrogenase, %FVC the percentage to predicted forced vital capacity, %DLCO the percentage to predicted diffusion capacity of carbon monoxide, SpO2 percutaneous oxygen saturation, PaO2 arterial partial pressure of oxygen, PaCO2 arterial partial pressure of carbon dioxide, IS immunosuppressive, LTOT long-term oxygen therapy